In October 2010 Photocure entered into an exclusive license agreement with Salix Pharmaceuticals for the development and commercialization rights to Lumacan®. Lumacan is a photodynamic colorectal diagnostic intended to significantly improve the detection of precancerous and cancerous lesions in the colon through fluorescence diagnosis. Salix has an exclusive worldwide license to Lumacan excluding the Nordic region. Salix is headquartered in Raleigh, North Carolina and develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases.
Salix web page
In September, 2011 Photocure entered into a strategic collaboration with Ipsen, a global specialty-driven biopharmaceutical company focused on four franchises, including uro-oncology, to commercialize Hexvix® worldwide, excluding the US and Nordic regions. Ipsen has a strong and well established uro-oncology franchise and will commercialize Hexvix through its dedicated urology sales force. Ipsen has its headquarter in Paris, France, and commercial presence in 49 countries. Photocure retained the rights to the product in the Nordics and the US.
Ipsen web page